<Immunization xmlns="http://hl7.org/fhir">
    <id value="England-Immunization-AdministrationOfSARSCoV2SecondDose-Example" />
    <extension url="https://fhir.hl7.org.uk/StructureDefinition/Extension-UKCore-VaccinationProcedure">
        <valueCodeableConcept>
            <coding>
                <system value="http://snomed.info/sct" />
                <code value="1324691000000104" />
                <display value="Administration of second dose of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccine" />
            </coding>
        </valueCodeableConcept>
    </extension>
    <identifier>
        <system value="https://tools.ietf.org/html/rfc4122" />
        <value value="7ec28d82-33bf-4e6d-a8de-91dcbc8d1802" />
    </identifier>
    <status value="completed" />
    <vaccineCode>
        <coding>
            <system value="http://snomed.info/sct" />
            <code value="39114911000001105" />
            <display value="COVID-19 Vaccine Vaxzevria (ChAdOx1 S [recombinant]) not less than 2.5x100,000,000 infectious units/0.5ml dose suspension for injection multidose vials (AstraZeneca UK Ltd)" />
        </coding>
    </vaccineCode>
    <patient>
        <reference value="Patient/1953684" />
        <type value="Patient" />
        <identifier>
            <system value="https://fhir.nhs.uk/Id/nhs-number" />
            <value value="9912003888" />
        </identifier>
    </patient>
    <occurrenceDateTime value="2021-02-23T13:00:08.476+00:00" />
    <primarySource value="false" />
    <reportOrigin>
        <text value="RR8 - LEEDS TEACHING HOSPITALS NHS TRUST" />
    </reportOrigin>
    <manufacturer>
        <display value="DREAMLAND Pharmaceuticals Ltd" />
    </manufacturer>
    <lotNumber value="R04X" />
    <protocolApplied>
        <doseNumberPositiveInt value="2" />
    </protocolApplied>
</Immunization>